Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Applied Genetic Technologies logo

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

Key Stats

Today's Range
$0.39
$0.39
50-Day Range
$0.37
$0.42
52-Week Range
$0.23
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Applied Genetic Technologies Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
2nd Percentile Overall Score

AGTC MarketRank™: 

Applied Genetic Technologies scored higher than 2% of companies evaluated by MarketBeat, and ranked 971st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Applied Genetic Technologies are expected to decrease in the coming year, from ($0.65) to ($0.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Applied Genetic Technologies has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for AGTC.
  • Dividend Yield

    Applied Genetic Technologies does not currently pay a dividend.

  • Dividend Growth

    Applied Genetic Technologies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AGTC.
  • Search Interest

    Only 1 people have searched for AGTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Applied Genetic Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Applied Genetic Technologies is held by insiders.

  • Percentage Held by Institutions

    Only 22.05% of the stock of Applied Genetic Technologies is held by institutions.

  • Read more about Applied Genetic Technologies' insider trading history.
Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
Genetic Technologies Limited (GENE)
See More Headlines

AGTC Stock Analysis - Frequently Asked Questions

Applied Genetic Technologies Co. (NASDAQ:AGTC) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/09/2021
Today
11/02/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-68,940,000.00
Pretax Margin
-21,537.54%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$0.26 per share

Miscellaneous

Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:AGTC) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners